Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial
Authors:
- John A. OrmistonJOJohn A. Ormiston
- Alexandre AbizaidAAAlexandre Abizaid
- John SpertusJSJohn Spertus
- Jean FajadetJFJean Fajadet
- Laura MauriLMLaura Mauri
- Joachim SchoferJSJoachim Schofer
- Stefan VerheyeSVStefan Verheye
- Joseph DensJDJoseph Dens
- Leif ThuesenLTLeif Thuesen
- Christophe DuboisCDChristophe Dubois
- Rainer HoffmannRHRainer Hoffmann
- William WijnsWWWilliam Wijns
Open Access
- 1 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 3 (6) , 556-564
Abstract
Background—: Drug-eluting stents reduce restenosis and reintervention rates but are complicated by stent thrombosis, which may be related to polymer coating. The NEVO sirolimus-eluting coronary stent (NEVO SES) is designed to improve long-term percutaneous coronary intervention safety by combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. Methods and Results—: NEVO ResElution-I was a prospective randomized study in 394 patients with coronary artery disease comparing the NEVO SES with the TAXUS Liberté paclitaxel-eluting coronary stent (TAXUS Liberté PES) stent. The primary end point was in-stent angiographic late loss at 6 months. Six months after percutaneous coronary intervention (PCI), the primary end point favored NEVO SES (0.13±0.31 mm versus 0.36±0.48 mm, P P =0.36; myocardial infarction: 2.0 versus 2.6%, P =0.75; target lesion revascularization: 1.5 versus 3.2%, P =0.33; major adverse cardiac events: 4.0 versus 7.4%, P =0.19. No stent thrombosis was observed with NEVO SES, whereas 2 cases occurred in TAXUS Liberté PES. Intravascular ultrasound showed lower percent volume obstruction for NEVO SES (5.5±11% versus 11.5±9.7%, P =0.016). Conclusions—: This trial proved the superiority of NEVO SES over TAXUS Liberté PES for the primary angiographic end point of in-stent late loss. No stent thrombosis occurred in the NEVO SES group. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00606333.Keywords
This publication has 28 references indexed in Scilit:
- Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent ThrombosisCirculation, 2009
- Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysisBMJ, 2008
- Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trialEuroIntervention, 2008
- A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery DiseaseJACC, 2007
- Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting StentsCirculation, 2005
- Impact of Sirolimus-Eluting Stents on Outcome in Diabetic PatientsCirculation, 2004
- Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients Insights from the RAVEL TrialEuropean Heart Journal, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation, 2003
- Stent implantation in acute myocardial infarctionThe American Journal of Cardiology, 1996